Cargando…
The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
The effect of thyroid stimulating endocrine (TSH) suppression medical aid on bone mineral density (BMD) of patients with differentiated thyroid carcinoma (DTC) or differentiated thyroid malignant neoplastic disease is still controversial. Our aim was to investigate the effect of TSH suppression ther...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726344/ https://www.ncbi.nlm.nih.gov/pubmed/36482589 http://dx.doi.org/10.1097/MD.0000000000031991 |
_version_ | 1784844757898362880 |
---|---|
author | Zou, Yang Li, Bin Wang, Xiaodong Mao, Jingxin Zhang, Yanyan |
author_facet | Zou, Yang Li, Bin Wang, Xiaodong Mao, Jingxin Zhang, Yanyan |
author_sort | Zou, Yang |
collection | PubMed |
description | The effect of thyroid stimulating endocrine (TSH) suppression medical aid on bone mineral density (BMD) of patients with differentiated thyroid carcinoma (DTC) or differentiated thyroid malignant neoplastic disease is still controversial. Our aim was to investigate the effect of TSH suppression therapy on BMD of patients with DTC. METHODS: A total of 1651 DTC patients with TSH-suppression medical care were analyzed by RevMan 5.3 software (https://training.cochrane.org/online-learning/core-software/revman/revman-5-download) in the present study. The PubMed and Embase databases were consistently hunted for works revealed through July 29, 2022. RESULTS: The results indicated that a significant association between femoral bone mineral density (FN-BMD) (P = .02) or lumbar spine bone mineral density (L-BMD) (P = .04) and DTC patients with TSH-suppression therapy. However, the total hip bone mineral density (TH-BMD) was not significantly related to DTC patients with TSH-suppression therapy (P = .11). For premenopausal women, it was shown that TH-BMD (P = .02) or L-BMD (P = .01) were closely related to DTC patients with TSH-suppression therapy. However, there was no relationship between FN-BMD and DTC patients with TSH-suppression therapy (P = .06). For postmenopausal women, TH-BMD was closely related to DTC patients with TSH-suppression therapy (P = .02). It was revealed that there was no significant difference between L-BMD (P = .16) or FN-BMD (P = .26) and DTC patients with TSH-suppression therapy. For men, there was no relationship between FN-BMD (P = .94) or L-BMD (P = .29) and DTC patients with TSH-suppression therapy. CONCLUSION: Our systematic review has demonstrated that TSH inhibition treatment mainly influence the TH-BMD or L-BMD of the DTC patients who were premenopausal women; the TH-BMD of the DTC patients who were postmenopausal women. In addition, there was no influence on the FN-BMD or L-BMD of the DTC patients who were men. |
format | Online Article Text |
id | pubmed-9726344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97263442022-12-09 The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer Zou, Yang Li, Bin Wang, Xiaodong Mao, Jingxin Zhang, Yanyan Medicine (Baltimore) 4300 The effect of thyroid stimulating endocrine (TSH) suppression medical aid on bone mineral density (BMD) of patients with differentiated thyroid carcinoma (DTC) or differentiated thyroid malignant neoplastic disease is still controversial. Our aim was to investigate the effect of TSH suppression therapy on BMD of patients with DTC. METHODS: A total of 1651 DTC patients with TSH-suppression medical care were analyzed by RevMan 5.3 software (https://training.cochrane.org/online-learning/core-software/revman/revman-5-download) in the present study. The PubMed and Embase databases were consistently hunted for works revealed through July 29, 2022. RESULTS: The results indicated that a significant association between femoral bone mineral density (FN-BMD) (P = .02) or lumbar spine bone mineral density (L-BMD) (P = .04) and DTC patients with TSH-suppression therapy. However, the total hip bone mineral density (TH-BMD) was not significantly related to DTC patients with TSH-suppression therapy (P = .11). For premenopausal women, it was shown that TH-BMD (P = .02) or L-BMD (P = .01) were closely related to DTC patients with TSH-suppression therapy. However, there was no relationship between FN-BMD and DTC patients with TSH-suppression therapy (P = .06). For postmenopausal women, TH-BMD was closely related to DTC patients with TSH-suppression therapy (P = .02). It was revealed that there was no significant difference between L-BMD (P = .16) or FN-BMD (P = .26) and DTC patients with TSH-suppression therapy. For men, there was no relationship between FN-BMD (P = .94) or L-BMD (P = .29) and DTC patients with TSH-suppression therapy. CONCLUSION: Our systematic review has demonstrated that TSH inhibition treatment mainly influence the TH-BMD or L-BMD of the DTC patients who were premenopausal women; the TH-BMD of the DTC patients who were postmenopausal women. In addition, there was no influence on the FN-BMD or L-BMD of the DTC patients who were men. Lippincott Williams & Wilkins 2022-12-02 /pmc/articles/PMC9726344/ /pubmed/36482589 http://dx.doi.org/10.1097/MD.0000000000031991 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 4300 Zou, Yang Li, Bin Wang, Xiaodong Mao, Jingxin Zhang, Yanyan The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
title | The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
title_full | The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
title_fullStr | The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
title_full_unstemmed | The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
title_short | The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
title_sort | risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer |
topic | 4300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726344/ https://www.ncbi.nlm.nih.gov/pubmed/36482589 http://dx.doi.org/10.1097/MD.0000000000031991 |
work_keys_str_mv | AT zouyang theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT libin theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT wangxiaodong theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT maojingxin theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT zhangyanyan theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT zouyang riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT libin riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT wangxiaodong riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT maojingxin riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer AT zhangyanyan riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer |